Premium
Questions regarding frontline therapy of acute myeloid leukemia
Author(s) -
Kantarjian Hagop,
O'Brien Susan
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.25281
Subject(s) - medicine , myeloid leukemia , context (archaeology) , bone marrow , myeloid , oncology , leukemia , induction therapy , intensive care medicine , bioinformatics , chemotherapy , biology , paleontology
The results from multiple investigations using different induction approaches suggest that better regimens are available and should be investigated further in the context of acute myeloid leukemia (AML) heterogeneity and emerging prognostic knowledge concerning cytogenetic and molecular abnormalities. Today, based on existing data, evaluating bone marrow on Days 10 to 14 for residual AML and reacting to the bone marrow findings may be a common practice, but is not validated by objective data.